title: Vanishing bile duct syndrome occurring after high-dose chemotherapy and autologous peripheral stem cell transplantation in a patient with Hodgkin's disease.
authors.forename: S
authors.initials: S
authors.lastname: Kömürcü
authors.forename: A
authors.initials: A
authors.lastname: Ozet
authors.forename: M K
authors.initials: MK
authors.lastname: Altundag
authors.forename: F
authors.initials: F
authors.lastname: Arpaci
authors.forename: B
authors.initials: B
authors.lastname: Oztürk
authors.forename: B
authors.initials: B
authors.lastname: Celasun
authors.forename: Y
authors.initials: Y
authors.lastname: Tezcan
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001761:Bleomycin / Q000009:adverse effects / Q000627:therapeutic use; D002780:Cholestasis, Intrahepatic / Q000209:etiology* / Q000503:physiopathology; D003131:Combined Modality Therapy / Q000009:adverse effects; D003606:Dacarbazine / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008297:Male; D013577:Syndrome; D014182:Transplantation, Autologous; D014747:Vinblastine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin